Drug name | Product name | Formulations/materials | Condition | Pre-clinical/clinical/approved | References |
---|---|---|---|---|---|
Cyclosporin | Restasis | Nanoemulsion | Dry eye | Approved | [189] |
Difluprednate | Durezol | Nanoemulsion | Eye inflammation | Approved | [189] |
Bevacizumab | – | PLGA /PCADK microspheres | Ocular angiogenesis | Pre-clinical | [184] |
Bevacizumab | – | Mesoporous silica nanoparticles | Ocular angiogenesis | Pre-clinical | [185] |
Bevacizumab | – | PLGA microspheres | Ocular angiogenesis | Pre-clinical | [189] |
Bevacizumab | – | Albuminated PLGA nanoparticles | Ocular angiogenesis | Pre-clinical | [190] |
Bevacizumab | – | Chitosan nanoparticles | Ocular angiogenesis | Pre-clinical | [191] |
Bevacizumab | – | PLA nanoparticles in porous PLGA microparticles | Ocular angiogenesis | Pre-clinical | [192] |
Bevacizumab | – | Multi-vesicular liposomes | Ocular angiogenesis | Pre-clinical | [193] |
Bevacizumab | – | Egg phosphatidylcholine:cholesterol (liposome) | Ocular angiogenesis | Pre-clinical | [194] |
Bevacizumab | – | OTX-IVT (anti-VEGF intravitreal hydrogel implant) | Ocular angiogenesis | Pre-clinical | [195] |
Bevacizumab | – | PLGA-PEG-PLGA hydrogel | Ocular angiogenesis | Pre-clinical | [196] |
Bevacizumab | – | Vinyl sulfone functionalized hyaluronic acid (HV-VS) and thiolated dextran (Dex-SH) hydrogel | Ocular angiogenesis | Pre-clinical | [197] |
Bevacizumab | – | Silk hydrogel | Ocular angiogenesis | Pre-clinical | [198] |
Bevacizumab | – | Poly(ethylene glycol)-poly-(serinol hexamethylene urethane) (ESHU) hydrogel | Ocular angiogenesis | Pre-clinical | |
Ranibizumab & Aflibercept | – | PLGA microspheres suspended in a PEG-PLLA-DA/NIPAA hydrogel | Ocular angiogenesis | Pre-clinical | |
Ranibizumab | Lucentis | Intravitreal injection | Myopic choroidal neovascularization/Diabetic retinopathy | Approved | [202] |
Ranibizumab | – | Non-biodegradable implant technology port delivery system | Ocular angiogenesis | Clinical Phase III trials | [203] |
Ranibizumab | – | Replenish posterior micropump | Ocular angiogenesis | Phase I trials | [204] |
Dexamethasone | Ozurdex | Biodegradable implant | Macular edema, Non-infectious uveitis | Approved | [205] |
Triamcinolone acetonide | Trivaris | Nanosuspension | Uveitis | Approved | [205] |
Triamcinolone acetonide | Kenalog | Nanosuspension | Macular edema | Approved | [205] |
Fluocinolone acetonide | Retisert | Non-biodegradable implant | Non-infectious Uveitis | Approved | [205] |
Fluocinolone acetonide | Iluvien | Non-biodegradable implant | Diabetic macular edema | Approved | [205] |
Triamcinolone acetonide | Triesence | Nanosuspension | Maculae edema | Approved | [205] |
Verteporfin | Visudyne | Liposome | AMD | Approved | [206] |
Aptamer | Macugen | Polymer nanoparticle | Wet AMD | Approved | [206] |
TLC399 (ProDex) | – | Lipid-based nanoparticle | Macular edema | Approved | [207] |
Latanoprost | Polat-001 | Liposome | Glaucoma | Approved | [207] |
Polyethylene glycol 400 & Propylene glycol | Systane | Nanoemulsion | Dry eye | Approved | [208] |